Brokerages Set MeiraGTx Holdings PLC (NASDAQ:MGTX) Target Price at $26.17

Posted by on Sep 12th, 2026

Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $26.1667.

MGTX has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of MeiraGTx in a report on Wednesday, July 8th. Zacks Research raised shares of MeiraGTx from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 13th. Wall Street Zen raised shares of MeiraGTx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Royal Bank Of Canada upped their target price on shares of MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, August 14th.

Read Our Latest Research Report on MeiraGTx

Insider Activity

In other MeiraGTx news, CFO Richard Giroux sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $12.51, for a total transaction of $700,560.00. Following the transaction, the chief financial officer owned 908,530 shares of the company’s stock, valued at approximately $11,365,710.30. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total transaction of $859,320.00. Following the sale, the chief executive officer owned 1,325,695 shares in the company, valued at $18,374,132.70. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 145,659 shares of company stock valued at $1,969,233. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MeiraGTx

A number of hedge funds have recently modified their holdings of MGTX. BNP Paribas Financial Markets lifted its position in shares of MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after acquiring an additional 1,466 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in MeiraGTx by 390.9% in the second quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after purchasing an additional 7,005 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of MeiraGTx during the 4th quarter worth $94,000. Abel Hall LLC acquired a new stake in MeiraGTx in the 4th quarter valued at approximately $98,000. Finally, Bank of Nova Scotia acquired a new stake in MeiraGTx in the 1st quarter valued at approximately $105,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Trading Down 0.5%

NASDAQ:MGTX opened at $12.79 on Monday. The stock’s 50 day moving average price is $13.20 and its 200 day moving average price is $10.71. MeiraGTx has a 52-week low of $6.62 and a 52-week high of $15.35. The company has a market capitalization of $1.23 billion, a PE ratio of 18.01 and a beta of 1.27. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.46) by $2.17. MeiraGTx had a net margin of 19.87% and a return on equity of 283.85%. The firm had revenue of $321.43 million during the quarter, compared to analysts’ expectations of $0.70 million. On average, research analysts anticipate that MeiraGTx will post 0.3 EPS for the current year.

About MeiraGTx

(Get Free Report)

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.

Read More

Analyst Recommendations for MeiraGTx (NASDAQ:MGTX)

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.